FADD levels in synovial fluids from OA-suffering, RA-suffering, and gout-suffering patients positively correlated with the inflammatory status of the joint evaluated by the number of leukocytes (Fig. 5g), strongly suggesting that soluble FADD could constitute a new biomarker of inflammation in rheumatic diseases. This evidence concerns the gene FADD and gout.